Premenstrual Dysphoric Disorder - Selective Serotonin Reupperation Inhibitors in the Regulation of Symptoms and the Positive Effects of Pharmacotherapy on the Quality of Life of Women With PMDD

Abstract

Premenstrual dysphoric disorder (PMDD) is a severe and disabling form of premenstrual syndrome that affects an average of 5% of women during their period. Studies show that the intense symptoms present during PMDD involve multiple factors, from genetic, ovarian or uterine, hormonal, neurological and psychological causes. These symptoms significantly impact the quality of life of women who suffer from this disorder, and serotonin inhibitors are considered the gold standard treatment for these cases, since they inhibit the release of hormones that stimulate the emergence of the aforementioned disorders. Therefore, the purpose of this chapter is to present the effectiveness of selective serotonin inhibitors (SSRIs) in the treatment of Premenstrual Dysphoric Disorder (PMDD). It is understood that studies have shown that SSRIs have reduced PMDD symptoms significantly. Likewise, each SSRI can cause particular adverse effects, which makes it necessary to choose the agent according to the characteristics of each patient.